Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMC

Concise review: cell therapy and tissue engineering for cardiovascular disease

Haraguchi Y., Shimizu T., Yamato M., Okano T.

Clinical Trial on Cardiovascular Disease, published in Stem Cells Transl Med (2012) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Stem Cells Transl Med (2012)
Reported sample size
—
Source database
Europe PMC
PMID
23197760
PMCID
PMC3659688
DOI
10.5966/sctm.2012-0030
Citations
60

Abstract (original English)

Cardiovascular disease is a major cause of morbidity and mortality, especially in developed countries. Various therapies for cardiovascular disease are investigated actively and are performed clinically. Recently, cell-based regenerative medicine using several cell sources has appeared as an alternative therapy for curing cardiovascular diseases. Scaffold-based or cell sheet-based tissue engineering is focused as a new generational cell-based regenerative therapy, and the clinical trials have also been started. Cell-based regenerative therapies have an enormous potential for treating cardiovascular disease. This review summarizes the recent research of cell sources and cell-based-regenerative therapies for cardiovascular diseases.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence
MyocardiumMyocytes, CardiacHumansCardiovascular DiseasesStem Cell TransplantationTransplantation, AutologousTissue EngineeringRegenerative MedicineCell SurvivalEmbryonic Stem Cells

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research